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Abstract
Background: Discrete choice experiments (DCEs) allow systematic assessment of preferences by
asking respondents to choose between scenarios. We conducted a labelled discrete choice
experiment with realistic choices to investigate patients' trade-offs between the expected health
gains and the burden of testing in surveillance of Barrett esophagus (BE).
Methods: Fifteen choice scenarios were selected based on 2 attributes: 1) type of test (endoscopy
and two less burdensome fictitious tests), 2) frequency of surveillance. Each test-frequency
combination was associated with its own realistic decrease in risk of dying from esophageal
adenocarcinoma. A conditional logit model was fitted.
Results: Of 297 eligible patients (155 BE and 142 with non-specific upper GI symptoms), 247
completed the questionnaire (84%). Patients preferred surveillance to no surveillance. Current
surveillance schemes of once every 1–2 years were amongst the most preferred alternatives.
Higher health gains were preferred over those with lower health gains, except when test
frequencies exceeded once a year. For similar health gains, patients preferred video-capsule over
saliva swab and least preferred endoscopy.
Conclusion: This first example of a labelled DCE using realistic scenarios in a healthcare context
shows that such experiments are feasible. A comparison of labelled and unlabelled designs taking
into account setting and research question is recommended.
Background
Discrete choice experiments (DCEs) have been proposed
as a means to improve systematic assessment of patients'
preferences regarding screening and surveillance pro-
grams [1]. It is suggested that traditional decision model-
ling and cost-utility analyses are insufficiently capable of
including process effects, such as patient burden, and
non-health outcomes, such as information, of diagnostic
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or therapeutic interventions [2] and that they fail to iden-
tify the most optimal program set-up from series of effi-
cient programs [1]. In the end, patient or population
preferences determine the acceptance of a program, and
hence the realization of the expected population health
gains. Current important areas of application include pri-
ority setting in health care (e.g., [3]), and patient prefer-
ences for characteristics of health care delivery (e.g, [4]) or
for treatment alternatives (e.g., [5]).
In a DCE, respondents are asked to choose between differ-
ent options, each of which is described by a series of
attributes at different levels [6-8]. The choices can be pre-
sented as labelled ('endoscopy') or unlabelled ('test A').
The majority of published DCEs in health care have used
unlabelled designs. Labelled designs offer less abstract
choices to respondents and this may add to the validity of
the results, although direct comparisons of labelled and
unlabelled designs are lacking so far. In both labelled and
unlabelled DCEs, the relative importance of the attributes,
and the trade-offs made between them, can be assessed
using statistical modelling.
The design of the experiment can be orthogonal, without
correlations between the attributes, but this may not
always be the most statistically efficient design. Non-
orthogonal efficient designs can be used to generate
designs with dependence between attributes and when
the choice probabilities are dependent on the attribute
levels [9]. Especially in labelled designs, it may not be pos-
sible to prevent such interdependence because, realisti-
cally, the levels of one attribute depend on the level of
another attribute. For example, choices would be unreal-
istic if one were to offer cancer screening at different inter-
vals with a lower detection rate for the frequent interval
compared to the infrequent one. Such unrealistic choices
will reduce respondents' interest and involvement with
the questionnaire, and might even lead to invalid choices.
Barrett esophagus (BE) is a condition in which the normal
squamous epithelium of the distal esophagus is replaced
by columnar epithelium of the intestinal type. Patients
with BE are at an increased risk of developing esophageal
adenocarcinoma (EAC). Therefore, they are recom-
mended to undergo regular endoscopic surveillance to
detect EAC at an earlier stage with more potential for a
curative treatment [10]. However, upper GI endoscopy is
an invasive procedure that is burdensome to patients and
is associated with anxiety and discomfort [11]. Further-
more, the number of patients experiencing this burden is
much larger than the number experiencing potential
health benefits from it, as the number of patients develop-
ing EAC in BE is low (an estimated 0.5% per year) [12-16].
Undisputed evidence that surveillance prolongs survival is
not available, although many studies indirectly imply that
it is beneficial [17-20].
These data underline the importance of including
patients' preferences in recommendations of regular
endoscopic surveillance, in addition to evidence on
expected health benefit. It is currently unknown, however,
how willing patients are to adhere to regular endoscopic
surveillance protocols given a specified expected health
benefit, if and how they make trade-offs between the bur-
den of testing and expected health benefits, and how their
preferences would change if a less invasive test were avail-
able.
The present study used a labelled and efficient DCE to
investigate patients' and potential future patients' prefer-
ences for regular endoscopic surveillance of BE. We
assessed the trade-offs patients are willing to make
between the burden of testing and the expected health
gain when choosing a surveillance scheme, with surveil-
lance schemes differing in test type, test frequency and the
resulting expected health benefits.
Methods
Respondents
We recruited patients with upper GI endoscopy experi-
ence, i.e., patients under regular surveillance for BE and
patients with non-specific upper GI symptoms (NS). We
approached consecutive patients who had participated in
a previous study assessing the burden of upper GI endos-
copy who had given permission to be contacted again,
within one year after having undergone an upper GI
endoscopy [11,21]. The Medical Ethics Committee of
Erasmus MC approved the study (MEC 03.1064). In total,
297 patients were eligible; 155 BE patients and 142 NS
patients. Inclusion criteria were:
- BE patients: presence of BE of 2 cm or more in length
confirmed by histological presence of intestinal metapla-
sia, absence of high-grade dysplasia and carcinoma, abil-
ity to read Dutch and informed consent. These patients
were participants to an ongoing trial assessing the value of
flow-cytometry in individualizing the frequency of sur-
veillance (CYBAR [22,23]).
- NS patients: referral for endoscopy for non-specific
upper GI symptoms, absence of "alarming symptoms",
absence of a prior diagnosis of BE, ability to read Dutch
and informed consent.
Questionnaire
• Selection of attributes and levels
We selected three potential determinants of patients' pref-
erences for surveillance: the invasiveness of the surveil-
lance test itself, the frequency of testing, and theBMC Medical Research Methodology 2009, 9:31 http://www.biomedcentral.com/1471-2288/9/31
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associated expected health gain. Their relevance as deter-
minants of preferences for endoscopic surveillance was
explored and confirmed in individual interviews with 30
BE patients.
We operationalized invasiveness as the 'type of surveil-
lance test', with three 'levels': endoscopy and two fictitious
less invasive tests: video capsule endoscopy and a saliva-
swab. Although the latter tests are not available for endo-
scopic surveillance, they are existing tests for other indica-
tions and therefore easy to describe and imagine.
Test frequency was presented as the number of times
patients would come for endoscopy within the next 10
years, with five levels (in 10 years time: 2, 3, 5, 10, and 40
times, respectively).
The health gain associated with each test-frequency com-
bination was described as the risk of dying from EAC in
the next 10 years. We estimated this risk to be 4% in
absence of surveillance (loosely based on a one-year risk
of detection of EAC of 0.5% [14] and a 5-year survival rate
of EAC of 10–20% [24]).
Results from the pilot study showed that patients had dif-
ficulties understanding unrealistic scenarios (e.g., increas-
ing test frequency with a more invasive test yielding a
lower expected health gain). Therefore, in our experiment
a given test that is performed at a given frequency
uniquely determined the associated health gain. Table 1
shows the health gains for each combination of test and
frequency in the DCE as based on expert opinion. Higher
test frequencies result in larger risk reductions, but at a
decreasing rate. At the same time, the effectiveness of
endoscopy is highest and that of the saliva test lowest, at
a given frequency.
￿ Experimental design
We used a labelled design, because the specific aspects of
endoscopy that determine its burdensomeness could not
be realistically presented to patients using the unlabelled
'test A' -variant. Patients were presented with 15 choices
between two scenarios, and additionally had the option
to choose not to undergo testing ('opt out'). Figure 1
shows an example of a choice as presented to the respond-
ents. Previous studies have demonstrated that respond-
ents are able to manage up to 16 choices [25,26].
A full-factorial, orthogonal design only provides optimal
efficiency in case the attributes do not affect the choice
probabilities [9] and does not allow for dependence
between the attributes. When non-zero effect sizes are
expected, more efficient (so called D-optimal or efficient)
designs can be obtained [27]. As we expected non-zero
effects of health gains and test frequency and there are
clear relationships between the attributes, we estimated a
simple linear model based on a small number of choice
sets. These estimates served as input for the SAS %Choic-
Eff macro [28]. This resulted in a near full-factorial effi-
cient design (surveillance by 2 times saliva swab in 10
years was used only once; 5 times saliva swab in 10 years
appeared three times) with a random order of appearance.
Presentation of questionnaire and elicitation mode
Each BE and NS patient received the same 15 choices. The
questionnaire started with an introduction explaining the
task and the attributes. NS patients were additionally
informed about the increased risk of EAC in BE patients,
and were asked to fill in the questionnaire as if they them-
selves had BE.
Three introductory questions were included to help
patients to get used to the attributes. Two final items to
check the validity of the DCE-results asked patients to
express directly which type of test they preferred overall
and how often they were reasonably willing to undergo
endoscopy at the most. BE patients were furthermore
asked to indicate their current surveillance frequency.
Pilot testing of the questionnaire in 3 BE and 4 NS
patients showed that the questionnaire was feasible and
that patients understood the task. We sent a paper version
of the questionnaire to all 297 patients. Follow-up
included a telephone call to answer questions, if neces-
sary, and to go through the first three choices together
with the respondent in order to assess his (or her) under-
standing of the task and to find out whether respondents
were prepared to make trade-offs.
Analyses
The Random Utility Model provides the theoretical basis
for the analysis of choice data [29]. It assumes that indi-
viduals choose the option that yields them the highest
utility. As it is unclear how patients trade off health gains
against test burden, represented by test type and fre-
quency, we did not impose functional restrictions on this.
Instead, each of the possible scenarios was represented
Table 1: Health gains (remaining 10-year risk of dying from EAC) 
for each combination of test and frequency in the discrete choice 
experiment (based on expert opinion and a baseline risk of 4% in 
the absence of surveillance [14,24,14].
10-year risk of dying (in %) at test frequency
Frequency (per 10 year): 2 3 5 10 40
Test:
Saliva swab 3.5 2.5 2.0 1.5 1.2
Video capsule 2.5 2.0 1.5 1.2 1.0
Endoscopy 2.0 1.5 1.2 1.0 0.9BMC Medical Research Methodology 2009, 9:31 http://www.biomedcentral.com/1471-2288/9/31
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with a dummy variable with the no-test option as the ref-
erence level. The utility of scenario j,  j  = 1,..,15, for
respondent i is then given by Uji = Uj + εji, with Uj repre-
senting the mean utility for scenario j and εji the respond-
ent specific deviation from the population mean.
Depending on the distributional assumptions on εji, the
choices of respondents can be modelled using logit or
probit specifications. As each question included a choice
between three options ('scenarios' – two surveillance
alternatives, and a no surveillance option) but only one
could be chosen, we used a conditional logit model. The
model was used to estimate the utilities, Uj, for the 15 test-
frequency combinations (as respondents chose one of
three alternatives in each choices set it is possible to esti-
mate up to 30 parameters from the answers to 15 choice
questions). These utilities have a relative interpretation
(i.e., a scenario with a higher utility is preferred over a sce-
nario with a lower utility). The model was estimated using
proc PHREG in SAS version 9.1 [30]. Differences between
groups (BE or NS) were tested by comparison of the like-
lihood of the overall model with the sum of the likeli-
hoods of the separate models for BE and NS (likelihood
ratio test). Effects of age and sex were studied in the same
way.
Results
Respondent characteristics and response
A total of 247 patients (133 BE and 114 NS) returned
completed questionnaires (response rate 84%). The mean
age of the respondents was 59 years, and the majority was
either employed (39.9%) or retired (43.2%) (Table 2). BE
patients were more often male than female. Most BE
patients underwent surveillance endoscopy once every
two years (86.9%). We were able to contact 71% of the
respondents (175/247) in the telephone follow-up. Some
of the patients wanted additional information or needed
help with the task, but most had already filled in the ques-
tionnaire (n = 109) or preferred to do this by themselves
(n = 30). All interviewed patients seemed to understand
the task and made trade-offs.
Preferences for test-frequency combinations
Table 3 shows the estimated utilities of the 15 scenarios
that were evaluated. All tests-frequency combinations
have a positive utility, indicating that they are preferred
over 'no test' and these effects were all significant (p <
0.01). The most preferred test was the video test at a fre-
quency of once a year, which achieved the highest esti-
mated utility of 6.03. This utility is significantly larger
than all other utilities, except compared to endoscopy
every one or two years. The combinations of endoscopy
every one or two years had the next highest utilities and
were significantly preferred over all other tests except
video capsule every one or two years. The p-values for
pair-wise comparisons of the utilities of all test-frequency
combinations are given in Table 4. For example, an
increase in frequency of endoscopy from once every two
years to each year, with an associated increase in expected
health gain, did not result in a significant increase in util-
ity (p = 0.85).
Figure 2 shows a graphical presentation of the results. The
horizontal zero utility line (x-axis) refers to not being
tested. The picture visualizes that higher test frequencies
which are associated with larger health gains are more
desirable than lower frequencies, up to a certain thresh-
old. For the video capsule and endoscopy, which are more
invasive than a saliva swab, raising test frequency to once
a year or more was associated with a decline in utility.
The results also indicate that for the same health gain
(which are shown as the bridging lines in Figure 2),
patients preferred video capsule over saliva swab, and
least preferred endoscopy (p < 0.05). For example, the
Example of a choice scenario as presented in the questionnaire Figure 1
Example of a choice scenario as presented in the questionnaire.BMC Medical Research Methodology 2009, 9:31 http://www.biomedcentral.com/1471-2288/9/31
Page 5 of 10
(page number not for citation purposes)
utility of video capsule 3x is larger than saliva swab 5x,
and endoscopy 2x, while all have the same health gain
(remaining risk of dying from EAC: 2%, see Table 1).
However, this only holds for test frequencies up to once
every year. For a decrease in the risk of dying form EAC
from 4.0% to 1.2%, which in our experiment could be
achieved by saliva swab 40x, video capsule 10x and endos-
copy 5x, endoscopy was preferred over saliva swab (p =
0.01, Table 4). At a risk of dying from EAC of 1%, annual
endoscopy is also preferred over quarterly tests with the
video capsule (p = 0.00).
Effects of patient characteristics
The model significantly improved when preferences were
estimated separately for BE and NS patients, for men and
women and for patients older or younger than 60 years
(likelihood ratio tests, all p-values < 0.001). Figure 3A
shows that BE patients assigned a larger utility to all test-
Table 2: Characteristics of participants
Variable All patients BE patients NS patients N
Group 247 (100%) 133 (53.8%) 114 (46.2%) 247
Hospital of origin: 247
- A 26 (10.5%) 26 (19.5%) 0
- B 39 (15.8%) 0 39 (34.2%)
- C 47 (19.0%) 47 (35.3%) 0
- D 135 (54.7%) 60 (45.1%) 75 (65.8%)
Mean age (sd) 59 (13) 62 (11) 56 (14) 247
Sex: male 141 (57.1%) 84 (63.2%) 57 (50%) 247
Civil status: 246
- married/living together 197 (80.1%) 108 (81.8%) 89 (78.1%)
- never married 18 (7.3%) 8 (6.1%) 10 (8.8%)
- divorced 15 (6.1%) 6 (4.5%) 9 (7.9%)
- widowed 16. (6.5%) 10 (7.6%) 6 (5.3%)
Employment 243
- paid work 97 (39.9%) 44 (33.3%) 53 (47.7%)
- no/unpaid 41 (16.9%) 22 (16.7%) 19 (17.1%)
- retired 105 (43.2%) 66 (50%) 39 (35.1%)
Education 242
- elementary 37 (15.3%) 21 (16.3%) 16 (14.2%)
- secondary 149 (61.6%) 77 (59.7%) 72 (63.7%)
- tertiary 56 (23.1%) 31 (24.0%) 25 (22.1%)
Endoscopic surveillance: once every two years N.a. 91 (86.9%) N.a. 132
Table 3: Estimated utility of test-frequency combinations (reference = no surveillance).
Coefficients (standard error)
Frequency (per 10 year): 2 3 5 10 40
Test:
Saliva swab 0.82
(0.32)∞
3.07
(0.22)*
3.99
(0.24)*
5.07
(0.29)*
5.32
(0.27)*
Video capsule 3.20
(0.22)*
4.55
(0.23)*
5.57
(0.28)*
6.03
(0.30)*
5.18
(0.29)*
Endoscopy 3.56
(0.24)*
4.89
(0.28)*
5.86
(0.30)*
5.89
(0.30)*
4.53
(0.30)*
* significantly different from no surveillance, p < 0.0001, ∞ p = 0.01BMC Medical Research Methodology 2009, 9:31 http://www.biomedcentral.com/1471-2288/9/31
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frequency combinations than NS patients. This difference
was significant for all scenarios (p < 0.05) except for a
saliva swab once every 5 or 3 years.
Men also gave all test-frequency combinations a higher
value than women (Figure 3B). The gender difference was
significant for all scenarios (p < 0.05), except for saliva
swab once every 5 years. Younger patients seemed to give
a higher utility to the saliva swab at any frequency com-
pared to patients older than 60, but this difference was not
statistically significant (p > 0.3), and not observed for the
other tests.
Despite the higher utility assigned by BE patients and by
men, the pattern of utilities was similar; with higher fre-
quencies being preferred over lower ones (up to a certain
point), and saliva swab being the least preferred. The pat-
terns differed in the fact that BE patients and men pre-
ferred endoscopy over the video capsule for testing up to
once a year and NS patients and women only for testing
up to every 3–5 years.
Direct preferences (validity tests)
The responses to the direct items showed that the video
capsule test was preferred by more patients (n = 103,
Table 4: Significance (p-values) for pair-wise comparisons of the utilities of all test-frequency combinations.
Saliva
swab
2×
Saliva
swab
3×
Saliva
swab
5×
Saliva
swab
10×
Saliva
swab
40×
Video
capsul
e 2×
Video
capsul
e 3×
Video
capsul
e 5×
Video
capsul
e 10×
Video
capsul
e 40×
Endos
copy
2×
Endos
copy
3×
Endos
copy
5×
Endos
copy
10×
Endos
copy
40×
Saliva 
swab 
2×
-
Saliva 
swab 
3×
<
.0001
-
Saliva 
swab 
5×
<
.0001
<
.0001
-
Saliva 
swab 
10×
<
.0001
<
.0001
<
.0001
-
Saliva 
swab 
40×
<
.0001
<
.0001
<
.0001
0.24 -
Video 
capsule 
2×
<
.0001
0.29 0.00 <
.0001
<
.0001
-
Video 
capsule 
3×
<
.0001
<
.0001
0.00 0.04 0.00 <
.0001
-
Video 
capsule 
5×
<
.0001
<
.0001
<
.0001
<
.0001
0.22 <
.0001
<
.0001
-
Video 
capsule 
10×
<
.0001
<
.0001
<
.0001
<
.0001
0.00 <
.0001
<
.0001
0.01 -
Video 
capsule 
40×
<
.0001
<
.0001
<
.0001
0.62 0.39 <
.0001
0.01 0.08 <
.0001
-
Endosc
opy 2×
<
.0001
0.01 0.00 <
.0001
<
.0001
0.11 0.01 <
.0001
<
.0001
<
.0001
-
Endosc
opy 3×
<
.0001
<
.0001
<
.0001
0.40 0.00 <
.0001
<
.0001
0.00 <
.0001
0.02 <
.0001
-
Endosc
opy 5×
<
.0001
<
.0001
<
.0001
<
.0001
0.01 <
.0001
<
.0001
0.16 0.30 0.00 <
.0001
<
.0001
-
Endosc
opy 
10×
<
.0001
<
.0001
<
.0001
<
.0001
0.01 <
.0001
<
.0001
0.10 0.23 0.00 <
.0001
<
.0001
0.85 -
Endosc
opy 
40×
<
.0001
<
.0001
0.01 0.01 <
.0001
<
.0001
<
.0001
<
.0001
<
.0001
<
.0001
<
.0001
0.03 <
.0001
<
.0001
-
Bold p-values highlight non-significant differencesBMC Medical Research Methodology 2009, 9:31 http://www.biomedcentral.com/1471-2288/9/31
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43%) than the saliva test (n = 65) and endoscopy (n = 60).
Twelve patients did not express a clear preference. The
maximum acceptable frequency of endoscopy from the
direct expressions was once a year (n = 122, 50%); or once
every two years (n = 84, 35%) for the majority of patients.
Only a few of the BE patients were willing to undergo
endoscopy more often (n = 15) or less often (n = 21).
Discussion
Main findings
This example of an analysis of patients' preferences for
surveillance of BE shows that using a labelled DCE with
dependency between attributes can add realism and is fea-
sible. Patients were prepared to make trade-offs between
the burden of surveillance and the expected health gain,
and preferences were supported by comparison with
direct preference questions. The findings indicate that the
current endoscopic surveillance schemes of once every
one or two years were amongst the most preferred alterna-
tives amongst patients, suggesting these are well accepted.
Strengths and weaknesses
This is, to the best of our knowledge, the first labelled DCE
in a health care setting that uses realistic scenarios associ-
ating each test-frequency combination with a specific
expected health gain. The great advantage of this design is
that it adds to the realism of the choices as presented to
the patients, and hence to the validity of the results. Using
a labelled design was deemed necessary as we considered
it impossible to convey the essential elements of the bur-
den of various tests without naming the test. Endoscopy
requires patients to swallow an instrument, which can be
associated with unpleasant sensations, such as belching,
nausea and vomiting. Labelling makes it possible to take
all essential elements into account, while an unlabeled
experiment requires each of these to be named separately
as an attribute (e.g. invasiveness, belching, nausea, vomit-
ing, etc). Moreover, each would have to be estimated sep-
arately, requiring a large number of observations, and
unrealistic choices would be generated (e.g. a non-inva-
sive test that causes vomiting).
We also considered it essential to fix the health gain asso-
ciated with a certain test-frequency combination, as
results from a pilot study showed that patients had diffi-
culties understanding choices in which health gain was
counter-intuitively. For example, respondents tended to
choose a scenario with more frequent testing because this
Utility of endoscopic surveillance by test and frequency (reference = no surveillance, the x-axis) Figure 2
Utility of endoscopic surveillance by test and frequency (reference = no surveillance, the x-axis).BMC Medical Research Methodology 2009, 9:31 http://www.biomedcentral.com/1471-2288/9/31
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A. Utility of endoscopic surveillance tests by patient type Figure 3
A. Utility of endoscopic surveillance tests by patient type. B. Utility of endoscopic surveillance tests by gender. C. Util-
ity of endoscopic surveillance test by age-group. BE: patients with Barrett esophagus. NS: patients with non-specific upper GI 
symptoms.BMC Medical Research Methodology 2009, 9:31 http://www.biomedcentral.com/1471-2288/9/31
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would incur a larger health gain, despite the scenario stat-
ing a lower health gain. It clearly was not possible to gen-
erate valid responses without associating health gain with
test-frequency. However, this also has some disadvan-
tages. First, it means that the attributes are correlated and
should not be analysed separately. We therefore did not
generate preferences for each attribute, but for each test-
frequency combination, thereby respecting the co-
dependency. We could thus not disentangle the utility
associated with the health gain from the attribute-specific
utilities associated with the invasiveness of the test and
the test frequency. Second, it limits the generalizability of
our results, as patients are likely to make different choices
when a different health gain would have been associated
with the scenarios. The baseline risk of dying of EAC in the
absence of surveillance of 4% in 10 years, however, is real-
istic for most Barrett patients [31]. The results of this study
may not hold for BE patients with high-grade dysplasia
who are at a higher risk of (dying from) EAC. Finally,
using uniquely determined health gains meant that we
could not check patients' understanding of the DCE using
a so-called 'dominant option' (a choice including one sce-
nario that is logically preferable at the level of all
attributes). The results of the direct preference assessment
items, nevertheless, validated the results; the video cap-
sule was the test most frequently preferred by patients in
the direct statements, and the most preferred endoscopy
frequency was once every one or two years.
This is also the first report of a systematic assessment of
patients' preferences for surveillance schemes. Subjects
had to make explicit choices between different test-fre-
quency combinations, each of them with their corre-
sponding health gain. In the 30 qualitative patient
interviews used to select the attributes and their levels,
many patients mentioned their tendency to follow their
doctor's advice and not being used to make deliberative
choices. Although all could well imagine the trade-offs in
the DCE, preferences may therefore have been constructed
by the DCE for some respondents, instead of the DCE
measuring pre-existing preferences [32]. However, this
limitation is not specific for our study but is applicable to
every formal preference assessment. In fact, we took
attempts to make the choice options as realistic as possi-
ble. Furthermore, NS patients also preferred endoscopy
once every one or two years, without being aware these are
the recommended frequencies.
Preferences for BE surveillance
Patients preferred being tested over not being tested.
Moreover, they preferred test-frequency combinations
with larger health gains, but for the more burdensome
tests, this was only up to a certain frequency of testing.
When the health gain was assumed to be similar, patients
preferred video-capsule over saliva swab and least pre-
ferred endoscopy. Although we cannot provide separate
estimates for the utility attributed to a certain health gain
or the utility of more frequent testing, it seems sensible to
suggest that more frequent testing and more burdensome
tests were preferred because of the higher health gain
incurred. Patients thus seem to optimise the health gain
incurred by more frequent and burdensome endoscopic
surveillance, up to a frequency of testing of around once a
year. The health gain associated with more frequent test-
ing than once a year does not outweigh the disutility of
such frequent testing.
We found some differences between respondent groups.
BE patients, who are under regular surveillance, attributed
more utility to all tests-frequency combinations than
patients with non-specific GI complaints. This means that,
given the same test, more BE patients would choose to
undergo the test than NS patients. This may relate to BE
patients having a better understanding of the feelings and/
or risks associated with having BE. The different age-distri-
bution of the respondent groups is unlikely to explain the
difference as the analysis by age did not show the same
pattern. Men also attributed more utility to being tested
then women, which might be attributed to different risk
attitudes of men and women.
Conclusion
This study shows that in the health care setting the appli-
cation of labelled DCEs adds realism and is feasible. Fur-
ther realism can be added by creating dependency
between some of the attributes. Although this might be
required if patients cannot cope with more complex
choices, it comes at the cost of analytical power.
This study furthermore indicates the importance of
research into the effectiveness of endoscopic surveillance
for patients with BE, and into reducing the test burden, for
example by optimising the test-frequency based on clini-
cal characteristics.
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